Publication | Closed Access

The anti-aggregation effects of ondansetron on platelets involve IP3 signaling and MAP kinase pathway, but not 5-HT3-dependent pathway

InflammationThrombosisMap Kinase PathwayThrombopoiesisSignal TransductionBlood PlateletMedicineHematologyHemostasisIp3 SignalingAnti-aggregation EffectsPlatelet AntagonistPharmacologyCell BiologyCell SignalingPlatelet Activation